0.89
+0.04(+4.71%)
Currency In CAD
Sector
Healthcare
Industry
Biotechnology
Employees
2
First IPO Date
November 05, 2021
| Name | Title | Pay | Year Born |
| Dr. Allen Warren Davidoff Ph.D. | Founder, Chief Executive Officer, President & Director | 552,086 | 1960 |
| Dr. Michael Scott Bumby D.V.M., M.B.A. | Chief Financial Officer | 9,184 | 1964 |
| Dr. Stephen Haworth M.D., MRCP | Chief Medical Officer | 155,686 | 1950 |
| Dr. Stacy Evans M.B.A., M.D. | Chief Business Officer | 222,015 | 1974 |
| Ms. Charlotte May | Corporate Secretary | 0 | N/A |
| Dr. David MacDonald Ph.D. | Consultant of Clinical Operations | 0 | 1963 |
| Nick Rigopoulos | Director of Communications | 0 | N/A |
| Dr. David Sans M.B.A., Ph.D. | Director of Corporate Development | 0 | 1970 |
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.